Efficacy and safety of intravenous vernakalant for rapid conversion of atrial fibrillation:A Systematic Review and meta-analysis
HU Ke,WEI Ying-luo,WANG Pu,HUANG He
DOI: https://doi.org/10.13333/j.cnki.cjcpe.2012.06.021
2012-01-01
Abstract:Objective This study focuses on systematic evaluation of the safety and the curative effect of intravenous vernakalant for rapid conversion of atrial fibrillation(AF).Methods Retrieve the related literature from Pub Med,Cochrane Central Register of Controlled Trials,The ISI Web of Knowledge Databases,EMBASE,www.clinicaltrials.gov,CBMdisc,CHKD,the time is ranging from the database′s initial construction to November 30,2011.In all the clinical trials for the vernakalant therapy of AF,three researchers will evaluate its quality and extract its information according to the The Grading of Recommendations Assessment,Development and Evaluation(GRADE) and then Meta analysis will be conducted on the results which meet the quality standard.Results Six randomized controlled trials(RCTs)(1 325 patients) met inclusion criteria and were included into this system. According to the outcomes of GRADE system,three are of high quality: the success rate of rapid conversion of paroxysmal AF,the success rate of rapid conversion of paroxysmal recent-onset AF,and the mortality;two of them were of moderate quality: the successrate of rapid conversion of persistent AF and the incidence of drug SAEs(serious adverse events).The following were the results of Meta analysis: ①Rapid conversion of paroxysmal AF: within 60 or 90 min,success rate of vernakalant group was superior to control group[50.15% vs 6.22%,OR 12.47, 95% CI(6.73,23.14),P<0.00001].②Rapid conversion rate of recent-onset AF:success rate of vernakalant group was superior to control group[57.02% vs 5.08%,OR 23.57,95% CI(11.86,46.85),P<0.00001] ③Rapid conversion rate of persistent AF: compared to control,vernakalant showed a higher rate of success,but there were no statistical difference between both groups [10.19% vs 1.30%,OR 6.31,95% CI(1.06,37.70),P=0.04].④Incidence of SAEs: there was no statistical difference between both groups [8.36% vs 9.26%,OR 0.95,95% CI(0.67,1.35),P=0.78]. ⑤Mortality rate:among the entire deaths one patient in the deaths was confirmed as vernakalant.Conclusion Vernakalant is effective and well-tolerated in the rapid conversion of recent-onset AF and paroxysmal AF,and will not increase the mortality rate and SAEs.